Drug Trial Radar · NCT03068455
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,844
Actual
Start
Apr 11, 2017
Primary completion
Jun 12, 2020
Study completion Feb 2, 2021
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma
Conditions
- Melanoma
Interventions
nivolumabBiological
Specified Dose on Specified Days
ipilimumabBiological
Specified Dose on Specified Days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free Survival (RFS) - All Randomized ParticipantsTime frame: From randomization to Primary Completion Date (up to approximately 3 years)
- Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%Time frame: From randomization to Primary Completion Date (up to approximately 3 years)
Locations
124 sites in 19 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona
The Angeles Clinic & Research Institute
Los Angeles, California
California Pacific Medical Center
San Francisco, California
University Of Colorado
Aurora, Colorado
Georgetown University Med Ctr
Washington D.C., District of Columbia
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
UF Health Cancer Center at Orlando Health
Orlando, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute
Atlanta, Georgia
University Of Chicago
Chicago, Illinois
Northwestern University
Chicago, Illinois
Oncology Specialists, S.C.
Park Ridge, Illinois
Mass General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University Of Michigan Health System
Ann Arbor, Michigan
Virginia Piper Cancer Institute
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School Of Medicine
St Louis, Missouri
NYU Langone Medical Center
New York, New York
Memorial Sloan Kettering Nassau
New York, New York
Carolinas Med Ctr
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Providence Cancer Center Oncology And Hematology Care
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
St. Luke's University Health Network
Easton, Pennsylvania
Local Institution
Nashville, Tennessee
Texas Oncology Sammons Cancer Center
Dallas, Texas
Md Anderson Can Cnt
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University Of Virginia Health System
Charlottesville, Virginia
Inova Melanoma and Skin Cancer Center
Fairfax, Virginia
University Of Washington Cancer Care Alliance
Seattle, Washington
Local Institution
North Sydney, New South Wales, Australia
Local Institution
Waratah, New South Wales, Australia
Local Institution
Westmead, New South Wales, Australia
Local Institution
Greenslopes, Queensland, Australia
Local Institution
Southport, Queensland, Australia
Local Institution
Woolloongabba, Queensland, Australia
Local Institution
Adelaide, South Australia, Australia
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.